Treating Psychosocial Distress in Glaucoma
NCT06053307
Summary
In this study, using three phases, the investigators will use an iterative development approach to refine a behavioral intervention for managing concomitant psychosocial distress in glaucoma. Phase 1: The investigators will begin by developing a baseline intervention using strategies from Acceptance and Commitment Therapy (ACT), and delivered using a mobile application. Phase 2: The investigators will refine the baseline intervention for glaucoma patients using qualitative interviews conducted with primary open-angle glaucoma (POAG) patients with psychosocial distress (N=20), and health professionals (N=5). Phase 3: Finally, the investigators will measure acceptability and feasibility of the refined intervention through a single-armed pilot study (N=25). The investigators hypothesize that the refined intervention will yield an acceptable and feasible intervention in a POAG patient population, setting the stage for a future efficacy study.
Eligibility
Inclusion Criteria * diagnosed with mild, moderate, or severe chronic glaucoma (e.g., POAG), * had a visual field within the past year at the main Duke Eye Center, * been prescribed pressure lowering eye drop medication, * at least mild distress (based on PHQ-4), * 18 years old, * able to understand, speak, and read English, and * be able to provide informed consent. Exclusion Criteria * diagnosed with borderline glaucoma or as a glaucoma suspect, * had a glaucoma surgery in past month (e.g., trabeculectomy, glaucoma drainage device/tube), * visual acuity of worse than 20/70 in the better seeing eye, * diagnosed with a major medical conditions (e.g., cancer, or another visual disorder, like macular degeneration), * diagnosed with a psychiatric conditions (e.g., schizophrenia, bipolar disorder), and * reported or suspected cognitive impairment indicated by provider or chart review.
Conditions4
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06053307